ASND - Ascendis Pharma AS Debt to Book Capitalization Ratio

Ascendis Pharma A/S (ASND) is making the therapy for rare endocrine disorders more convenient, fostering strong brand loyalty. On the GURU.Markets platform, the company's debt-to-book capitalization ratio demonstrates capital dynamics, where 0.32 captures the current value of the indicator. This is based on the TransCon system, which establishes closed treatment standards, and active R&D with high efficiency in launching new products.

ASND (Ascendis) Debt to Book Value history from 07/04/2022 to 10/27/2026

Ascendis Pharma AS (ASND) - metric breakdowns and financial figures

- price and consensus price forecast:

Stock Price Ascendis Pharma A/S|ASND - Analyst Consensus Forecast

- market capitalization data:

Market Value Ascendis|ASND - Value Adjusted for Debt and Cash

- book capitalization data:

Net Assets per Single Share Ascendis Pharma|ASND - Company Net Assets|Market Capitalization to Book Value Ratio ascendispharma.com|ASND - Company Total Assets

- debt and liquidity data:

Total Debt to Equity Ratio Ascendis Pharma A/S|ASND - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ascendis Pharma Inc.|ASND - Company Total Debt|Debts to Book Capitalization Ascendis

Fundamental company analysis:Ascendis Pharma A/S - ASND

Core merchandise of Ascendis Pharma Inc.

This ratio compares total debt obligations to the market value of equity, allowing for an assessment of the actual level of financial leverage within the price action. By analyzing the history of the debt-to-equity ratio, an investor can see the resilience of Ascendis Pharma (ASND), which prefers organic growth and partnerships over mergers, thereby minimizing the risk of overloading the balance sheet with borrowed capital while scaling technologies.

Competitors of Ascendis Pharma A/S (ASND)